BACKGROUND: CD69 is expressed in several hemopoietic cells and is an early activation marker in chronic lymphocytic leukemia. Chronic lymphocytic leukemia is a clinically heterogeneous disease which needs novel prognostic parameters which can be easily and efficiently managed. DESIGN AND METHODS: We investigated CD69 by flow cytometry in a series of 417 patients affected by chronic lymphocytic leukemia and compared this to other biological and clinical prognosticators. RESULTS: CD69 was associated with Rai stages (P=0.00002), β(2)-microglobulin (P=0.0005) and soluble CD23 (P<0.0001). CD69 and ZAP-70 (P=0.018) or CD38 (P=0.00015) or immunoglobulin variable heavy chain gene mutations (P=0.0005) were also significantly correlated. Clinically, CD69 positive chronic lymphocytic leukemias received chemotherapy more frequently (74%; P<0.0001), and presented a shorter duration of response after fludarabine plus rituximab (P=0.010) as well as shorter progression free survival and overall survival (P<0.0001). CD69 demonstrated true additive prognostic properties, since the CD69(+) plus ZAP-70(+) or CD38(+) or immunoglobulin variable heavy chain gene unmutated patients had the worst progression free survival and overall survival (P<0.0001). Interestingly, low CD69 expression was necessary to correctly prognosticate the longer progression free survival of patients with a low tumor burden of β(2)-microglobulin (P=0.002), of soluble CD23 (P=0.020), or of Rai stages 0-I (P=0.005). CD69 was confirmed to be an independent prognostic factor in multivariate analysis of progression free survival (P=0.017) and overall survival (P=0.039). CONCLUSIONS: Our data indicate that CD69 is significantly correlated with poor clinical and biological prognostic factors and is confirmed to be an independent disease prognosticator. This supports its introduction in a routine laboratory assessment and, possibly, in a prognostic scoring system for chronic lymphocytic leukemia, after an adequate standardization process.
BACKGROUND:CD69 is expressed in several hemopoietic cells and is an early activation marker in chronic lymphocytic leukemia. Chronic lymphocytic leukemia is a clinically heterogeneous disease which needs novel prognostic parameters which can be easily and efficiently managed. DESIGN AND METHODS: We investigated CD69 by flow cytometry in a series of 417 patients affected by chronic lymphocytic leukemia and compared this to other biological and clinical prognosticators. RESULTS:CD69 was associated with Rai stages (P=0.00002), β(2)-microglobulin (P=0.0005) and soluble CD23 (P<0.0001). CD69 and ZAP-70 (P=0.018) or CD38 (P=0.00015) or immunoglobulin variable heavy chain gene mutations (P=0.0005) were also significantly correlated. Clinically, CD69 positive chronic lymphocytic leukemias received chemotherapy more frequently (74%; P<0.0001), and presented a shorter duration of response after fludarabine plus rituximab (P=0.010) as well as shorter progression free survival and overall survival (P<0.0001). CD69 demonstrated true additive prognostic properties, since the CD69(+) plus ZAP-70(+) or CD38(+) or immunoglobulin variable heavy chain gene unmutated patients had the worst progression free survival and overall survival (P<0.0001). Interestingly, low CD69 expression was necessary to correctly prognosticate the longer progression free survival of patients with a low tumor burden of β(2)-microglobulin (P=0.002), of soluble CD23 (P=0.020), or of Rai stages 0-I (P=0.005). CD69 was confirmed to be an independent prognostic factor in multivariate analysis of progression free survival (P=0.017) and overall survival (P=0.039). CONCLUSIONS: Our data indicate that CD69 is significantly correlated with poor clinical and biological prognostic factors and is confirmed to be an independent disease prognosticator. This supports its introduction in a routine laboratory assessment and, possibly, in a prognostic scoring system for chronic lymphocytic leukemia, after an adequate standardization process.
Authors: Giovanni Del Poeta; Maria Ilaria Del Principe; Maria Antonietta Irno Consalvo; Luca Maurillo; Francesco Buccisano; Adriano Venditti; Carla Mazzone; Antonio Bruno; Laura Gianní; Giovanni Capelli; Francesco Lo Coco; Maria Cantonetti; Valter Gattei; Sergio Amadori Journal: Cancer Date: 2005-12-15 Impact factor: 6.860
Authors: Liguang Chen; John Apgar; Lang Huynh; Frank Dicker; Teresa Giago-McGahan; Laura Rassenti; Arthur Weiss; Thomas J Kipps Journal: Blood Date: 2004-10-28 Impact factor: 22.113
Authors: Maria Ilaria Del Principe; Giovanni Del Poeta; Adriano Venditti; Francesco Buccisano; Luca Maurillo; Rita Marini; Maria Christina Cox; Paola Panetta; Giovanna Suppo; Massimo Degan; Antonio Bruno; Valter Gattei; Sergio Amadori Journal: Haematologica Date: 2004-12 Impact factor: 9.941
Authors: R Bomben; M Dal Bo; A Zucchetto; E Zaina; P Nanni; P Sonego; G Del Poeta; M Degan; V Gattei Journal: Leukemia Date: 2005-08 Impact factor: 11.528
Authors: Antonella Zucchetto; Riccardo Bomben; Michele Dal Bo; Paolo Sonego; Paola Nanni; Maurizio Rupolo; Pietro Bulian; Luigino Dal Maso; Giovanni Del Poeta; Maria Ilaria Del Principe; Massimo Degan; Valter Gattei Journal: J Cell Physiol Date: 2006-05 Impact factor: 6.384
Authors: Antonella Zucchetto; Riccardo Bomben; Michele Dal Bo; Paola Nanni; Pietro Bulian; Francesca Maria Rossi; Maria Ilaria Del Principe; Simone Santini; Giovanni Del Poeta; Massimo Degan; Valter Gattei Journal: Cytometry B Clin Cytom Date: 2006-07-15 Impact factor: 3.058
Authors: Rajendra N Damle; Sonal Temburni; Carlo Calissano; Sophia Yancopoulos; Taraneh Banapour; Cristina Sison; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi Journal: Blood Date: 2007-08-07 Impact factor: 22.113
Authors: Riccardo Bomben; Michele Dal Bo; Daniela Capello; Dania Benedetti; Daniela Marconi; Antonella Zucchetto; Francesco Forconi; Rossana Maffei; Emanuela M Ghia; Luca Laurenti; Pietro Bulian; Maria Ilaria Del Principe; Giuseppe Palermo; Mia Thorsélius; Massimo Degan; Renato Campanini; Anna Guarini; Giovanni Del Poeta; Richard Rosenquist; Dimitar G Efremov; Roberto Marasca; Robin Foà; Gianluca Gaidano; Valter Gattei Journal: Blood Date: 2007-04-01 Impact factor: 22.113
Authors: Maria Ilaria Del Principe; Giovanni Del Poeta; Francesco Buccisano; Luca Maurillo; Adriano Venditti; Antonella Zucchetto; Rita Marini; Pasquale Niscola; Maria Antonietta Irno Consalvo; Carla Mazzone; Licia Ottaviani; Paola Panetta; Antonio Bruno; Riccardo Bomben; Giovanna Suppo; Massimo Degan; Valter Gattei; Paolo de Fabritiis; Maria Cantonetti; Francesco Lo Coco; Domenico Del Principe; Sergio Amadori Journal: Blood Date: 2006-04-06 Impact factor: 22.113
Authors: Lawrence R Shiow; David B Rosen; Nadezda Brdicková; Ying Xu; Jinping An; Lewis L Lanier; Jason G Cyster; Mehrdad Matloubian Journal: Nature Date: 2006-03-08 Impact factor: 49.962
Authors: Sylvia Ganghammer; Julia Gutjahr; Evelyn Hutterer; Peter W Krenn; Susanne Pucher; Claudia Zelle-Rieser; Karin Jöhrer; Maikel Wijtmans; Rob Leurs; Martine J Smit; Valter Gattei; Richard Greil; Tanja N Hartmann Journal: Haematologica Date: 2015-11-20 Impact factor: 9.941
Authors: Kallesh D Jayappa; Vicki L Gordon; Christopher G Morris; Briana Wilson; B Dharmaveer Shetty; Konrad J Cios; Puja C Arora; Krista M Isaac; Shekhar Saha; Timothy P Bender; Michael E Williams; Craig A Portell; Michael J Weber Journal: Blood Adv Date: 2021-09-14
Authors: Alex J Cornish; Phuc H Hoang; Sara E Dobbins; Philip J Law; Daniel Chubb; Giulia Orlando; Richard S Houlston Journal: Blood Adv Date: 2019-01-08